’Balversa (erdafitinib, Janssen),’ which has been approved as a targeted therapy for bladder cancer, has reportedly applied for reimbursement 2 years after being approved in Korea.

It is believed that the company is seeking Balversa’s entry into Korea’s health insurance market based on its proven effectiveness in patients who have used immuno-oncology drugs.

According to industry sources on the 6th, Janssen’s Balversa recently applied for a reimbursement decision to Korea’s Health Insurance Review and Assessment Service.

Balversa was approved by the Ministry of Food and Drug Safety in January 2022. Specifically, the drug is indicated for the treatment of adult patien